Beyond Principal-Component Analysis of the Positive and Negative Syndrome Scale in Patients With Schizophrenia
Dear Editor:
Canciel and others (1) add their study of Positive and Negative Syndrome Scale (PANSS)-rated symptoms of schizophrenia to the growing literature indicating that 5 symptom factors are necessary to account for symptoms of the disorder. They note many similarities in the items contained in each factor across studies but also allude to several differences that may be related to the study sample's clinical characteristics. Other possible reasons for differences in factor composition may be related to sample size and to the limitations of the principalcomponent method. Indeed, principalcomponent factor analysis is recognized as an exploratory method. We wish to bring attention to our large-scale, multicentre study of the PANSS factor structure. In it, we use the more rigorous method of confirmatory factor analysis (2) . In a sample of 1233 subjects with schizophrenia, we found that groups varying widely in age, chronicity, and illness phase did not significantly differ in their symptom structure. We identified a 5-factor structural model of the PANSS that met statistical criteria for good model fit. The criterion of good fit is an index of the degree of correspondence between the order in sample data and in the proposed model. Our model used 25 of the 30 PANSS items, organized into 5 factors: negative, positive, activation, dysphoric mood, and autistic preoccupation. Although identification of a good-fit model establishes the model's internal consistency, validity studies are necessary to demonstrate model utility. The model's discriminant validity has been demonstrated in a study of sex differences in the relation of homelessness to symptom severity (3), in a study of symptom differences between familial and deficit-syndrome schizophrenia (4) , and in a study of the association between symptoms and cognitive-perceptual deficits in schizophrenia (5) . Symptom subscales based upon this model have been published, as have tables of norms based upon an adult population with chronic schizophrenia (6) . Leonard 
Olanzapine-Induced Hair Loss
Olanzapine is a thienobenzodiazepine atypical neuroleptic that is generally considered safe and well tolerated, compared with typical neuroleptics. However, we wish to inform clinicians of a potential toxicity associated with its use; that is, hair loss.
A 41-year-old Asian woman was admitted to hospital with a 5-year history of bizarre behaviour and erotomanic and persecutory delusions. She believed that her ex-employer was pursuing her and harassing her with messages sent via television and radio because she refused to engage in a relationship. She also believed that he had bribed her coworkers and tenants with 1 million dollars to harass her and cause water damage to her rental property.
Olanzapine (Zyprexa Zydis) 5 mg daily was initiated in hospital, and the dosage was increased to 15 mg daily over the subsequent 4 weeks. Within 2 weeks of starting olanzapine, at 7.5 to 10 mg daily, she reported gradually increasing hair loss. The hair loss accelerated when the daily dosage was increased to 15 mg. She complained of losing a handful of hair after washing or brushing it, and often found her pillow and bed sheet covered with hair in the morning. Although there was no hair count, the hair loss was obviously distressing her and was witnessed by the treatment team.
The patient continued to express delusional beliefs, and we suspected noncompliance when nursing staff noted the patient vigorously brushing her tongue shortly after taking the Zydis wafer. This was confirmed when her serum olanzapine concentration was found to be 35 nmol/L (at 10 mg taken orally daily, the average level is reported to be 74 nmol/L [1] ). Because the patient did not improve and was distressed by the side effect, we switched olanzapine to risperidone over a 1-week period. As the olanzapine dosage was reduced with the addition of risperidone, the patient reported decreased hair loss. Noncompliance to oral medications remained a problem, and she was eventually switched to flupenthixol depot, with no further complaint of hair loss. The patient was not taking any other medications prior to admission, and olanzapine was the only medication she was taking during the period of hair loss. She was otherwise healthy and had no concurrent Can J Psychiatry, Vol 47, No 9, November 2002 W 891
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